Key points are not available for this paper at this time.
New initiation of LABAs or LAMAs in patients with COPD is associated with an approximate 1.5-fold increased severe cardiovascular risk, irrespective of prior CVD status and history of exacerbations.
Wang et al. (Tue,) studied this question.